ArticleBioImpacts : BI2018
Microfluidic paper-based analytical devices (µPADs) for fast and ultrasensitive sensing of biomarkers and monitoring of diseases.
Article in BioImpacts : BI, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Microfluidic paper-based analytical extraction devices (µPAEDs): a cost-effective and portable solution for biomarkers, contaminants and VOC detection.Mikrochimica acta · 2025Review
- A Review on Optical Biosensors for Monitoring of Uric Acid and Blood Glucose Using Portable POCT Devices: Status, Challenges, and Future Horizons.Biosensors · 2025Review
- Detection of SARS-CoV-2 Based on Nucleic Acid Amplification Tests (NAATs) and Its Integration into Nanomedicine and Microfluidic Devices as Point-of-Care Testing (POCT).International journal of molecular sciences · 2023Review
- Diagnosis of acute myocardial infarction: highlighting cardiac troponins as vital biomarkers.BioImpacts : BI · 2023Article
- Paper-based biosensors as point-of-care diagnostic devices for the detection of cancers: a review of innovative techniques and clinical applications.Frontiers in oncology · 2023Review
- A Distance-Based Microfluidic Paper-Based Biosensor for Glucose Measurements in Tear Range.Applied biochemistry and biotechnology · 2022Article
- Current Challenges and Future Trends of Enzymatic Paper-Based Point-of-Care Testing for Diabetes Mellitus Type 2.Biosensors · 2021Review
- Hepatitis C Diagnosis: Simplified Solutions, Predictive Barriers, and Future Promises.Diagnostics (Basel, Switzerland) · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Through the development of analytical techniques, microscaled devices have displayed attractive advantages, including ultrasensitive detection and analysis, cost-effectiveness, portability, process integrity, multi-process functionality, and in-situ analysis. In the last decade, a new generation of analytical devices has emerged based on the cellulose materials - so-called microfluidic paper-based analytical devices (µPADs) - a field that will change the face of the diagnosis of different diseases and sensing of a wide range of biological/chemical/biochemical phenomena. The main aim of the current editorial is to highlight the importance of the µPADs in the research and development of diagnostic devices and pharmaceuticals.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.